Regenxbio's RGX-202 Hits Primary Endpoint in Pivotal Duchenne Trial, Clearing Path to a 2027 Accelerated-Approval Filing
Regenxbio's gene therapy RGX-202 met the primary endpoint of its pivotal Phase III AFFINITY DUCHENNE trial, with 93% of participants reaching the microdystrophin expression threshold.
4 min read3 sources